ClinicalTrials.gg
CompletedNCT03185793Updated Aug 7, 2019

Dose-finding and Safety Study of SHR4640 in Subjects With Hyperuricemia

A Phase 2 interventional study of Placebo and SHR4640 in Hyperuricemia, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2019-08-07.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
198
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies testing ruzinurad in Hyperuricemia — 1 open to participants now, 1 under way, none of them phase 3. ruzinurad · Hyperuricemia.

Enrollment
2nd of 11
198 · median 34
Started
2017
with 1 other
Phase 2
3 of 11
1 open now
Registered
3rd of 11
by date
Lead sponsor
10 of 11
Jiangsu HengRui Medicine Co., Ltd.

Among the 11 studies testing ruzinurad in Hyperuricemia, this one is the 2nd largest by enrollment, is one of 2 that started in 2017, is one of 3 in phase 2, and was the 3rd registered.

Hyperuricemia

240 studies on the registry are indexed under Hyperuricemia; 44 are open to participants now.

Browse Hyperuricemia studies →

Open to participants now

1 of the 11 studies testing ruzinurad in Hyperuricemia is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

About ruzinurad

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 29 Hyperuricemia studies recruiting now, 8 (28%) set no upper age limit and 13 (45%) stop at 75 or younger; 1 takes children under 18; 6 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing ruzinurad in Hyperuricemia, or all of them as a file.
02

Study summary

The objective of the study is to assess efficacy and safety of SHR4640 in subjects with hyperuricemia.

03

Conditions studied

  • Hyperuricemia

Browse trials for

Keywords

  • SHR4640, Phase II, monotherapy, dose-finding
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18-70 years, male or female;
  2. Subject meets one of the following conditions:
  1. Subject with a history of gout has a serum uric acid ≥480μmol/l at screening; 2) Subject with a history of hyperuricemia has a serum uric acid ≥540μmol/l at screening, and requiring long-term uric acid-lowering therapy per the investigator's judgment; 3) Subject with a history of hyperuricemia has a serum uric acid≥480μmol/l at screening, on stable treatment for hypertensive, hyperlipidemia or diabetes for at least 3 month, and requiring long-term uric acid-lowering therapy per the investigator's judgment; 3. 18kg/m2≤ ≤32kg/m2.

Exclusion criteria

Exclusion Criteria:

  1. Subject who is pregnant or breastfeeding;
  2. or Aspartate aminotransferase or total >1.5 upper normal limit;
  3. Estimated (MDRD formula) ˂60ml/min;
  4. ˃8%;
  5. Subject with known or allergy to SHR4640 or any component of SHR4640;
  6. Subject with a history of ;
  7. Subject with a history of urolithiasis, or positive findings on ultrasound examination at screen
  8. Subject within the last 3months has: myocardial infarction, angina, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, cerebral infarction, cerebral hemorrhage, subarachnoid hemorrhage, or transient ischemia attack;
  9. Subject has acute gout flares within 2 weeks before randomization;
  10. Subject who is taking any other urate-lowering medication (allopurinol, febuxostat, probenecid and benzbromarone) that is indicated within 2 weeks before randomization and can not stop during the study;
  11. Subject who is taking more than 100mg once daily or unstable dosage aspirin within 2 weeks before randomization and can not stop during the study;
  12. Subject who is taking any diuretic within 2 weeks before randomization and can not stop during the study.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
198 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    placebo for 5 weeks

    Drug: Placebo

  • Experimental
    2.5mg SHR4640

    SHR4640 for 5 weeks

    Drug: SHR4640

  • Experimental
    5mg SHR4640

    SHR4640 for 5 weeks

    Drug: SHR4640

  • Experimental
    10mg SHR4640

    SHR4640 for 5 weeks

    Drug: SHR4640

  • Active comparator
    50mg benzbromarone

    Benzbromarone for 5 weeks

    Drug: benzbromarone

Interventions

  • DrugPlacebo

    Placebo once daily for 5 weeks

  • 1mg SHR4640 once daily for a week, 2.5mg, 5mg or 10mg SHR4640 once daily for 4 weeks

  • 25mg benzbromarone once daily for a week, 50mg benzbromarone once daily for 4 weeks

06

What researchers measure

Primary outcomes

  1. Proportion of subjects with a serum uric level≤360μmol/l.

    Time frame: Week 5

Secondary outcomes

  1. Actual change from baseline in serum uric level.

    Time frame: Week 5

  2. Percentage change from baseline in serum uric level .

    Time frame: Week 5

  3. Rate of gout flares requiring treatment.

    Time frame: Up to week 5

  4. Incidence of gout flares requiring treatment.

    Time frame: Up to week 5

  5. Proportion of subjects with a serum uric level≤360μmol/l

    Time frame: At week1, 2, 3 and 4

  6. Proportion of subjects with a serum uric level consistent ≤360μmol/l

    Time frame: At week 3, 4 and 5

  7. Actual change from baseline in serum uric level

    Time frame: At week 1, 2, 3 and 4

  8. Percentage change from baseline in serum uric level

    Time frame: At week 1, 2, 3 and 4

07

Study locations

1 site
  • Jiangsu Hengrui Medicine Co., Ltd.
    Shanghai, Shanghai 200127, China
08

References and documents

Publications

  • Lin Y, Chen X, Ding H, Ye P, Gu J, Wang X, Jiang Z, Li D, Wang Z, Long W, Li Z, Jiang G, Li X, Bi L, Jiang L, Wu J, Guo L, Cai X, Lu X, Chen Q, Chen H, Peng A, Zuo X, Ning R, Zhang Z, Tai Y, Zhang T, Bao C. Efficacy and safety of a selective URAT1 inhibitor SHR4640 in Chinese subjects with hyperuricaemia: a randomized controlled phase II study. Rheumatology (Oxford). 2021 Nov 3;60(11):5089-5097. doi: 10.1093/rheumatology/keab198. PubMed 33693494 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2017 to primary completion in Jul 2018, 12 months.

Of 24 phase 2 interventional studies under Hyperuricemia, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2017
First posted
Jun 14, 2017
StartActual
Jul 20, 2017
Primary completionActual
Jul 20, 2018
CompletionActual
Jul 20, 2018
Last update
Aug 7, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03185793
Responsible party
Sponsor
First posted
Jun 14, 2017
Start date
Jul 20, 2017
Primary completion
Jul 20, 2018
Completion
Jul 20, 2018
Last update
Aug 7, 2019

Study contacts

Chunde Bao
principal investigator · Shanghai Jiaotong University School of Medicine,Renji Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ruzinurad

Start the discussion